



Research Article

Visualizing the Distribution of Matrix Metalloproteinases in Ischemic Brain Using In Vivo ^{19}F -Magnetic Resonance Spectroscopic Imaging

Vincent J. Huber,¹ Hironaka Igarashi ,¹ Satoshi Ueki,¹ Mika Terumitsu-Tsujita,² Chikako Nito,³ Ken Ohno,¹ Yuji Suzuki ,¹ Kosuke Itoh,¹ Ingrid L. Kwee,⁴ and Tsutomu Nakada^{1,4}

¹Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata, Niigata, Japan

²Administrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan

³Department of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan

⁴Department of Neurology, University of California Davis, Davis, CA, USA

Correspondence should be addressed to Hironaka Igarashi; higara@bri.niigata-u.ac.jp

Received 13 June 2018; Accepted 13 September 2018; Published 6 January 2019

Academic Editor: Alexey P. Kostikov

Copyright © 2019 Vincent J. Huber et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Matrix metalloproteinases (MMPs) damage the neurovascular unit, promote the blood-brain barrier (BBB) disruption following ischemic stroke, and play essential roles in hemorrhagic transformation (HT), which is one of the most severe side effects of thrombolytic therapy. However, no biomarkers have presently been identified that can be used to track changes in the distribution of MMPs in the brain. Here, we developed a new ^{19}F -molecular ligand, TGF-019, for visualizing the distribution of MMPs in vivo using ^{19}F -magnetic resonance spectroscopic imaging (^{19}F -MRSI). We demonstrated TGF-019 has sufficient sensitivity for the specific MMPs suspected in evoking HT during ischemic stroke, i.e., MMP2, MMP9, and MMP3. We then utilized it to assess those MMPs at 22 to 24 hours after experimental focal cerebral ischemia on MMP2-null mice, as well as wild-type mice with and without the systemic administration of the recombinant tissue plasminogen activator (rt-PA). The ^{19}F -MRSI of TGN-019-administered mice showed high signal intensity within ischemic lesions that correlated with total MMP2 and MMP9 activity, which was confirmed by zymographic analysis of ischemic tissues. Based on the results of this study, ^{19}F -MRSI following TGN-019 administration can be used to assess potential therapeutic strategies for ischemic stroke.

1. Introduction

Matrix metalloproteinases (MMPs) are essential to normal brain function [1–3]; however, they can become highly toxic to the brain in pathological situations, such as cerebral ischemia, where they evoke degradation in tissue integrity via the neuroinflammatory cascade. This cascade eventually leads to cerebral edema and hemorrhagic transformation (HT), a life-threatening complication of cerebral ischemia [4]. Moreover, MMP inhibition was shown to ameliorate tissue damage and preserve the

blood-brain barrier in animal ischemia models [5]. Three in MMP family members, MMP2, MMP9 (referred to as the gelatinases), and MMP3, are thought to be activated within the ischemic lesion where they are critical to injury progression during and after cerebral ischemia [6, 7]. Of these MMPs, the concentration of MMP9 rises significantly in ischemic tissue consequent to thrombolytic therapy using the tissue plasminogen activator (tPA), the current gold-standard for treating acute stage ischemia. The rise of MMP9 was found to strongly correlate with increased risk of HT [8].

Visualization of MMP distribution in vivo would not only provide insights into tissue disintegration within the ischemic lesion but also enable the prediction of deleterious edema and HT. Some in vivo applicable techniques were developed for this specific purpose [9, 10], and however, they generally require relatively long-waiting times (ca. 4 to 24 hours) to reveal postadministration MMP distribution. Consequently, an in vivo method for visualizing MMP distribution during the acute stage of cerebral ischemia immediately following tracer administration would be extremely valuable. In response to that need, we developed the small molecule ^{19}F -magnetic resonance (MR) ligand TGF-019 based on the broad-spectrum MMP inhibitor galardin (GM-6001), which has high affinity for MMP2, 3, and 9 [11]. TGF-019 visualization utilized the in vivo ^{19}F -MR method first developed by Nakada, which has an advantage in the lack of ^{19}F -background due to fluorinated compounds in the brain [12–14]. Using TGF-019, we visualized MMP distribution under three relevant sets of conditions using a mouse model of focal cerebral ischemia and correlated the average TGF-019 signal intensities in the brain region and individual MMP levels by the conventional methods following brain extraction.

2. Methods

2.1. Synthesis of TGF-019. TGF-019 (Figure 1) was synthesized as a diastereotopic mixture starting from racemic(5-fluoro)tryptophan, shown schematically in Figure S1 and as described in detail in the supplementary materials section of this paper (Supporting Material). (Rac)-2-[(ethoxycarbonyl)methyl]-4-methylpentanoic acid was obtained from American Biochemicals (College Station, TX, USA) and was used as received. Additional reagents were sourced from Sigma-Aldrich (Tokyo, Japan), Wako Pure Chemical Industries (Osaka, Japan), TCI (Tokyo, Japan), or Nacalai Tesque (Kyoto, Japan) and were used as received. Analytical thin-layer chromatography (TLC) was performed using Sigma-Aldrich F254 indicating TLC plates, which were visualized under UV light, unless otherwise noted. ^1H -nuclear magnetic resonance (NMR) spectra were recorded at 300 MHz on a Varian Mercury 300 spectrometer (Varian Inc, Palo Alto, CA, USA) and were referenced to an internal tetramethylsilane (TMS) standard, unless otherwise indicated. Analytical ultra-performance liquid chromatography (UPLC) and high-resolution mass spectroscopy (HRMS) were performed on a Waters (Milford, MA, USA) Acquity UPLC combined with a Waters LCT Premier XE mass detector, with additional UPLC data obtained using Waters Acquity UPLC PDA and ELS detectors.

The chemical properties of TGF-019 and its key intermediates were in agreement with those expected based on the assigned structures and were found to be similar to those described for nonfluorinated analogs [15]. UPLC analysis of the synthesized TGF-019 indicated it was obtained in 95% chemical purity as a 2.4:1 mixture of unresolved diastereomers. The product composition was further confirmed by HRMS analysis of the diastereomeric mixture




FIGURE 1: Chemical structure of TGF-019. Synthetic methods were shown schematically in Figure S1 and described in the supplemental materials section of the online version of this paper.

(mass calculated for $\text{C}_{20}\text{H}_{28}\text{FN}_4\text{O}_4$ ($\text{M}+\text{H}^+$), 407.2089; found, 407.2074 (3.6 ppm)). Prior to in vivo studies, a sample of TGF-019 was converted to its sodium salt by treatment with an equimolar amount of NaOH in ultrapure water, which was then lyophilized to give a powdered material suitable for reconstitution into an appropriate vehicle. No degradation in compound purity of the sodium salt was observed by UPLC/HRMS.

2.2. In Vitro MMP Inhibition. The ability of TGF-019 to interact with MMP2, MMP3, and MMP9 was evaluated using an in vitro inhibition assay (Supporting Material). In this assay, outsourced to Eurofins Panlabs Discovery Services (Taipei, Taiwan), TGF-019 was shown to completely inhibit MMP2 and MMP9, with a somewhat weaker, but significant inhibition of MMP3. This suggests increased MMP expression following ischemic injury can be visualized using TGF-019.

2.3. Animal Preparation. The study was approved by the institutional animal care and use committee of University of Niigata (61-6, 121-3) and carried out in accordance with the guidelines set forth by the U.S. National Institutes of Health regarding the care and use of animals for experimental procedures. MMP2 knockout mice [16] (RBRC00398) were provided by RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. Twenty-two adult male mice, C57BL/6, and twenty-one MMP2 knockout mice (26–30 g each) were maintained under standard laboratory conditions with a 12 h/12 h light/dark cycle. Food and water were available ad libitum, except for 10 h prior to MCA occlusion, during which food was withheld to prevent hyperglycemia.

2.4. Intracranial MMP Administration. To evaluate the sensitivity of TGF-019 to MMP2, MMP3, and MMP9, we injected each MMP individually into the cerebral hemisphere of MMP2 KO mice ($n = 2/\text{MMP}$) [17] and imaged using ^{19}F -MRSI following TGF-019 administration. MMP2 KO mice were chosen to avoid the background signal of baseline MMP2 in the normal brain. Under urethane anesthesia (1.2 g/kg intraperitoneal injection), the head of the

mouse was fixed in a stereotaxic device, and 2 μ l of 0.1 μ g/ μ l pro-MMP2, MMP3, pro-MMP9, or activated-MMP9 was injected 0.1 mm anterior to the bregma, 1.5 to 2 mm lateral to the midline, and 1 to 3.5 mm below the skull surface using a 30-gauge Hamilton syringe. The injection was performed over 15 min and was followed by MR measurement. Activation of pro-MMP9 was performed according to the method of Collier et al. [18].

2.5. Experimental Ischemic Stroke Models. Thirteen MMP2 knockout mice (the MMP2 KO group), eleven C57BL/6 mice with saline administration (the WT saline group), and eleven C57/BL6 mice with rt-PA administration (the t-PA group) were employed for the experimental ischemic stroke model. Mice were anesthetized with 1–1.2% isoflurane in 30% oxygen and 70% nitrous oxide administered through a face mask, with the animals breathing spontaneously. Rectal temperature was maintained at $37 \pm 0.5^\circ\text{C}$ using a temperature control unit and heating pad during the anesthesia period. Oxygen saturation (SpO₂) was monitored throughout the operation procedure utilizing a pulse oximeter Mouse Ox (STARR Life Sciences Co, Oakmont, PA, USA) with probe placement on the left thigh. Regional cerebral blood flow (rCBF) was measured continuously starting immediately prior to and throughout the 60 min interval of induced focal ischemia using laser-Doppler flowmetry (ALF21, Advance Co., Tokyo, Japan). The Doppler probe was affixed to the skull 1 mm posterior and 6 mm laterally to the bregma. C57BL/6 animals received a continuous i.v. infusion of r-tPA, 10 mg/kg, dissolved in 0.3 ml normal saline for 30 minutes starting 15 minutes before recirculation. Control animals were given an identical volume of saline.

Transient focal cerebral ischemia was induced using a modified version of the procedure [19] described by Yang et al. [20]. The right middle cerebral artery (MCA) was occluded by introducing a 6-0 silicone-coated monofilament into the internal carotid artery to a point 6 mm distal to the internal carotid artery and pterygopalatine arterial bifurcation. Success of the MCA occlusion was confirmed in mice fulfilling the following three conditions: greater than 93% of SpO₂ throughout the operation procedure, greater than 80% decrease in rCBF (CBF%) at 15–20 min following the ischemic insult relative to the preischemia level, and a neurological deficit score of 2 or greater at 30 min after ischemia after allowing the mouse to regain consciousness. Neurological deficit scoring was done using the criteria established by Amiry-Moghaddam et al. [21]: normal motor function, 0; flexion of the torso and contralateral forelimb upon lifting the animal by the tail, 1; circling to the contralateral side but normal posture at rest, 2; leaning to the contralateral side at rest, 3; and no spontaneous motor activity, 4. The filament was removed under anesthesia 60 min after ischemia induction.

2.6. In Vivo ¹⁹F-MRSI Acquisition and Data Analysis. Under anesthesia with an intraperitoneal administration of urethane (1.2 g/kg), 100 mg/kg TGF-019 dissolved in 0.2 ml

saline was administered for about 30 seconds through tail vein 1 h following intracranial MMP administration or at 22 to 24 h after the induction of ischemia. Mice were then placed into the MR magnet on their backs in a custom-made Plexiglas stereotactic holder. The head was fixed in a position by ear and tooth bars. Rectal temperature was maintained at $37 \pm 0.5^\circ\text{C}$ using a custom-designed temperature control system.

MRI experiments were performed on a 15 cm bore 7T horizontal magnet (Magnex Scientific, Abingdon, UK) with a Agilent Unity-INOVA-300 system (Agilent Inc., Palo Alto, CA, USA) equipped with an actively shielded gradient. A custom-made volume transmit and quadrature surface receive ¹H-¹⁹F double tune coil (Takashima Seisaku-Syo, Hino, Japan) was used for both ¹H-anatomical MRI and ¹⁹F-MRSI. After acquisition of a ¹H-T₂-weighted image (TR/effective TE; 2000/80 m-sec, echo train; 8, echo spacing; 20 ms, field of view; 16 \times 16 mm, image matrix 128 \times 128, slice thickness; 2 mm), ¹⁹F-spin echo MRSI was acquired starting at 30 min post-TGF-019 administration using the following parameter settings: TR/TE; 1000/2.5 m-sec, field of view 16 \times 16 mm, image matrix 16 \times 16, spectral width 19841 Hz/2048 point, slice thickness 4 mm, number of acquisitions 16, and total scan time 68 min.

Data were processed using conventional 3D-FT. For chemical shift dimension, 40 Hz of exponential apodization was applied as a noise filter to both sides of the echo signals. For spatial dimensions, sine bell apodization was applied to avoid intervoxel signal contamination, and the matrix was zero filled to a 64 \times 64 matrix. Spatial resolution was then enhanced to a 128 \times 128 matrix by cubic interpolation. The MRSI map was coregistered on to T₂-weighted image, and the average signal intensity of TGF-019 within the infarcted area is shown by T₂-weighted imaging, as well the contralateral hemisphere was measured to compare signal intensities among all three groups. Data processing was done using VNMR3.2 software (Agilent Inc., Palo Alto, CA, USA).

2.7. Assay of MMPs. Fifteen mice (five mice in each group) subjected to experimental ischemic stroke were used for the assay of MMPs. Under deep anesthesia using 200 mg/kg pentobarbital, the brain was extracted, and each hemisphere was cut 2 mm posterior from the frontal apex in 4 mm thick slices. Tissues were homogenized in the working buffer (50 mM Tris-HCl (pH 7.4), 1 μ M ZnCl₂, 5 mM CaCl₂, and 0.05% Brij35) [22]. Gelatin zymography was used to evaluate the activities of MMP2 and MMP9 according to the method described by Yang et al. [23] with some modifications. The gels were scanned on a densitometer (SH-9000, Corona, Ibaraki, Japan). A mixture of human MMP9 and MMP2 (Primary Cell Co. Ltd. Sapporo, Japan) served as gelatinase standards. MMP3 was determined by ELISA using an anti-MMP3 antibody (LF-EK50675 Mouse MMP-3, Ab frontier, Seoul, Korea).

2.8. Statistical Procedure. Statistics were performed with SPSS software (IBM corp., Armonk, NY, USA). Data were tested with one-way analysis of variance with the Bonferroni




FIGURE 2: ^{19}F -MRSI of MMPs intracranially administered in the MMP2 knockout mice brain. MRSI color images were coregistered and superimposed with T_2 -weighted ^1H -MRI. (a) Pro-MMP9, (b) activated MMP9, (c) pro-MMP2, or (d) pro-MMP3 was administered at 30 min before intravenous administration of TGF-019.

correction for multiple comparison. Data were expressed as mean \pm standard error of the mean (SEM). Significance was considered where $P < 0.05$.

3. Results

3.1. Sensitivity of TGN-019 against MMPs. In the brains administrated with a microdose (approximately $0.2\ \mu\text{g}$) of pro-MMP2, MMP3, pro-MMP9, or activated MMP9, ^{19}F -signals corresponding to TGF-019 were clearly detected 30 min following a 200 mg/kg intravenous administration of the ligand (Figure 2). All eight mice survived the procedure.

3.2. Visualizing the Distribution of MMPs in Ischemic Stroke. Following the MCA occlusion, nine mice in each of the C57BL/6 and MMP2 KO groups survived throughout the experiments. Infarcted tissue was indicated in the right MCA perfused area of all twelve mice studied by MR. The signal intensity of TGF-019 within the ischemic lesion delineated by T_2 -weighted imaging was significantly stronger than the nonischemic contralateral hemisphere in sufficient signal-to-noise ratio (23.7 in ischemic cortex, Figure 3). Of those groups, TGF-019 signal intensities were strongest in the t-PA group followed by the WT-saline group, while those of the

MMP2 KO group were found to be the weakest (Figure 4 and Figure 5(a), $p < 0.05$, ANOVA with Bonferroni correction). Optical zymographic densities also showed significantly higher densities in the ischemic hemisphere than the contralateral hemisphere (Figure 5(b)). Conversely, MMP3 did not show a significant increase among all areas in this experimental procedure (Figure 5(c)). Signal intensities of TGN-019 and zymographic optical densities of MMP2/9 were found to be highly correlated in the range shown by the experiments (Figure 5(d)).

4. Discussion

TGF-019 is fluorinated derivative of pan-MMP inhibitor galardin (GM-6001), which has a high affinity for MMP2, MMP9, and MMP3 ($K_i \cong 0.5, 0.2,$ and $30\ \text{nM}$, resp.) [24], and penetrates the blood-brain barrier into the extracellular space of the brain parenchyma where MMPs exist and mainly play a physiological role in extracellular matrix regulation [25]. Physiologically, the basal distribution of MMPs consists of pro-MMP2, MMP3, and MMP14 (MT1-MMP) within extracellular space, while only a small amount of other MMPs are thought to be present [26]. Given the high affinity of galardin for those MMPs




FIGURE 3: ^{19}F MRSI spectra in regions of interest. (a) T2-weighted image of representative t-PA-administered mouse shows the prominent infarct area in the right MCA area. Grid shows phase-encoded voxels in nonzero-filled/interpolated MRSI data. Each colored square corresponds to the voxel of region-of-interest (ROI) in which (b) the spectra of identical color was detected.





FIGURE 4: Continued.



(c)

FIGURE 4: Representative MR images of the mice ischemia model. T₂-weighted images (the left column) and ¹⁹F-MRSI coregistered and superimposed with T₂-weighted images (the right column) of ischemia with intravenous administration of the saline (WT-saline) group (a), ischemia with intravenous administration of t-PA (t-PA) group (b), and MMP2 knockout (MMP2 KO) group (c).




FIGURE 5: Changes of MMPs at 22 to 24 hours after 60 minutes of ischemia. (a) TGF-019 signal intensities in the ischemic area (ipsilateral, closed bar) and nonischemic (contralateral, open bar) area. $n = 4$ per group. (b) MMP2 and MMP9 combined activity (MMP2/9) demonstrated by zymography. t-PA groups showed the strongest activity in the ischemic area. $n = 5$ per group. (c) Protein levels of MMP3 did not show the significant changes among ischemic lesions. $n = 5$ per group. (d) Signal intensities of TGF-019 and activities of MMP9/2 demonstrated by zymography were highly correlated in the range showed in the experiments. * $P < 0.05$ vs ischemic area of the WT-saline group, ** $P < 0.01$ vs ischemic area of the WT-saline group, § $P < 0.05$ vs nonischemic area of the WT-saline group, §§ $P < 0.01$ vs nonischemic area of the WT-saline group.

(MMP14 Ki \cong 13.4 nM), TGF-019 signal intensity in normal brain tissue likely reflects its interaction with background levels of pro-MMP2, MMP3, and MMP14.

In the acute ischemic lesion, TGF-019 images showed significant MMP upregulation, and the resulting signal intensities correlated with the total proteolytic activity of

MMP2 and MMP9. In particular, levels of activated MMP9 drastically increase during acute stage cerebral ischemia, which is pivotal in the cascade leading to neurovascular unit injury, especially deterioration of the blood-brain barrier [27]. Furthermore, tPA treatment further increased TGF-019 signal intensity within the ischemic lesion concomitant with increased MMP2/9 proteolytic activity, which was previously reported [8]. MMP2 is also upregulated in the ischemic lesion, and however, only moderate levels of MMP2 induction were reported in experimental cerebral ischemia [28]. While MMP3 also appears to be activated during acute stage ischemia and is also thought to contribute to neurovascular unit injury [29], no increase in its level were found in the three groups included in this study, which was also consistent with a prior report involving temporally MCA occluded mice [7]. One study did show a significant rise in MMP3 protein levels 24 h after the induction of cerebral ischemia [30], and however, the study involved a photochemically-induced permanent ischemia model, which may be responsible for the differences in MMP3 expression compared to the present study. Therefore, based on the currently available evidence, we believe the rise in TGF-019 signal intensity in our animal model primarily reflects MMP9 induction and upregulation within the ischemic lesion, although we should note that TGF-019 MRS would not discriminate MMP9 among other MMP family members.

Using TGF-019 as a potent tracer to visualize the distribution of MMP family members focusing on in vivo and future clinical studies, there are two main issues to be solved. One is the potential toxicity of TGF-019. In this study, we did not notice any behavioral changes after 100 mg/kg TGF-019 administration in MMP-treated mice, although we did not evaluate long-term behavioral or pathological changes. It was reported that administration of another broad-spectrum MMP family inhibitor, BB-94, evoked increased apoptosis in a cerebral hemorrhage model of mice [31]. However, GM-6001 at 180 mg/kg single dose, which is about twice the dose of TGF-019 used in the present study, did not show adverse effects and improved locomotor activities at seven days after induction of MCA occlusion [25]. Another issue is the relatively high dose (100 mg/kg) used in this study. Since we could detect the TGF-019 spectra with a high signal-to noise ratio ($S/N \cong 7$ in normal tissue, $S/N \cong 21$ in the ischemic lesion, resp., Figure 3) from small voxel ($4 \mu\text{m}^3$), it will be feasible to utilize TGF-019 at smaller doses than 100 mg/kg for a large object.

5. Conclusion

In summary, we synthesized TGF-019, a fluorinated compound with high-affinity to several MMP family members, and visualized their distribution in vivo using ^{19}F -MRSI. Signal intensities of TGF-019 correlated to MMP2/9 activities, which were measured by zymography. While further studies will be necessary to confirm the relative contributions of the individual TGF-019 stereoisomers during ^{19}F -MRSI, ^{19}F -MRSI following TGF-019 administration can be used to elucidate the pathological role of MMPs during

cerebral ischemia and to assess potential therapeutic strategies for ischemic stroke.

Data Availability

The imaging data and numerical data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors' Contributions

V J H planned the project, synthesized the TGF-019, and wrote the manuscript. H I planned the project, prepared animals, measured the MRSI, and wrote the manuscript. S U and Y S manipulated the animals. K O measured MRSI. M T prepared and manipulated animals. C N assayed the extracted specimens. K I handled the image analysis and statistical analysis. I L K provided critical suggestion and wrote the manuscript. T N provided basic MRSI measurement idea and commented on the manuscript.

Acknowledgments

Professor Tsutomu Nakada died on July 1, 2018, prior to the acceptance of this manuscript. We acknowledge his contributions to this research and manuscript. The authors thank Ms. Tae Ikarashi for her technical assistance. This research was funded by Grants-in-Aid (25461310, 16K15574, and 18H02767) from the Japan Society for the Promotion of Science.

Supplementary Materials

The supplementary material represents synthesis and in vitro MMP inhibition of TGF-019. (*Supplementary Materials*)

References

- [1] E. Tsilibary, A. Tzinia, L. Radenovic et al., "Neural ECM proteases in learning and synaptic plasticity," *Progress in Brain Research*, vol. 214, pp. 135–157, 2014.
- [2] X. X. Wang, M. S. Tan, J. T. Yu, and L. Tan, "Matrix metalloproteinases and their multiple roles in Alzheimer's disease," *BioMed Research International*, vol. 2014, Article ID 908636, 8 pages, 2014.
- [3] R. E. Vandembroucke and C. Libert, "Is there new hope for therapeutic matrix metalloproteinase inhibition?," *Nature Reviews Drug Discovery*, vol. 13, no. 12, pp. 904–908, 2014.
- [4] Y. Yang and G. A. Rosenberg, "Matrix metalloproteinases as therapeutic targets for stroke," *Brain Research*, vol. 1623, pp. 30–38, 2015.
- [5] R. R. Sood, S. Taheri, E. Candelario-Jalil, E. Y. Estrada, and G. A. Rosenberg, "Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain," *Journal*

- of *Cerebral Blood Flow and Metabolism*, vol. 28, no. 2, pp. 431–438, 2008.
- [6] J. Kurzepa, J. Kurzepa, P. Golab, S. Czernska, and J. Bielewicz, "The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke," *International Journal of Neuroscience*, vol. 124, no. 10, pp. 707–716, 2014.
 - [7] S. Hafez, M. Abdelsaid, S. El-Shafey, M. H. Johnson, S. C. Fagan, and A. Ergul, "Matrix metalloprotease 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke," *Stroke*, vol. 47, no. 3, pp. 843–851, 2016.
 - [8] T. Sumii and E. H. Lo, "Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats," *Stroke*, vol. 33, no. 3, pp. 831–836, 2002.
 - [9] N. Liu, J. Shang, F. Tian, H. Nishi, and K. Abe, "In vivo optical imaging for evaluating the efficacy of edaravone after transient cerebral ischemia in mice," *Brain Research*, vol. 1397, pp. 66–75, 2011.
 - [10] S. Chen, J. Cui, T. Jiang et al., "Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke," *Journal of Cerebral Blood Flow and Metabolism*, vol. 37, no. 1, 2015.
 - [11] J. L. Hao, T. Nagano, M. Nakamura, N. Kumagai, H. Mishima, and T. Nishida, "Galardin inhibits collagen degradation by rabbit keratocytes by inhibiting the activation of pro-matrix metalloproteinases," *Experimental Eye Research*, vol. 68, no. 5, pp. 565–572, 1999.
 - [12] T. Nakada, I. L. Kwee, and C. B. Conboy, "Noninvasive in vivo demonstration of 2-fluoro-2-deoxy-D-glucose metabolism beyond the hexokinase reaction in rat brain by 19F nuclear magnetic resonance spectroscopy," *Journal of Neurochemistry*, vol. 46, no. 1, pp. 198–201, 1986.
 - [13] T. Nakada, I. L. Kwee, P. J. Card, N. A. Matwiyoff, B. V. Griffey, and R. H. Griffey, "Fluorine-19 NMR imaging of glucose metabolism," *Magnetic Resonance in Medicine*, vol. 6, no. 3, pp. 307–313, 1988.
 - [14] I. L. Kwee, H. Igarashi, and T. Nakada, "Aldose reductase and sorbitol dehydrogenase activities in diabetic brain: in vivo kinetic studies using 19F 3-FDG NMR in rats," *Neuroreport*, vol. 7, no. 3, pp. 726–728, 1996.
 - [15] R. Hirayama, M. Yamamoto, T. Tsukida et al., "Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors," *Bioorganic and Medicinal Chemistry*, vol. 5, no. 4, pp. 765–778, 1997.
 - [16] T. Itoh, T. Ikeda, H. Gomi, S. Nakao, T. Suzuki, and S. Itoharu, "Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice," *Journal of Biological Chemistry*, vol. 272, no. 36, pp. 22389–22392, 1997.
 - [17] G. A. Rosenberg, M. Kornfeld, E. Estrada, R. O. Kelley, L. A. Liotta, and W. G. Stetler-Stevenson, "TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase," *Brain Research*, vol. 576, no. 2, pp. 203–207, 1992.
 - [18] I. E. Collier, S. M. Wilhelm, A. Z. Eisen et al., "H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen," *Journal of Biological Chemistry*, vol. 263, no. 14, pp. 6579–6587, 1988.
 - [19] H. Igarashi, V. J. Huber, M. Tsujita, and T. Nakada, "Pre-treatment with a novel aquaporin 4 inhibitor, TGN-020, significantly reduces ischemic cerebral edema," *Neurological Sciences*, vol. 32, no. 1, pp. 113–116, 2011.
 - [20] G. Yang, P. H. Chan, J. Chen et al., "Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia," *Stroke*, vol. 25, no. 1, pp. 165–170, 1994.
 - [21] M. Amiry-Moghaddam, T. Otsuka, P. D. Hurn et al., "An alpha-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain," *Proceedings of the National Academy of Sciences*, vol. 100, no. 4, pp. 2106–2111, 2003.
 - [22] H. R. Lijnen, J. Silence, G. Lemmens, L. Frederix, and D. Collen, "Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system," *Thrombosis and Haemostasis*, vol. 79, no. 6, pp. 1171–1176, 1998.
 - [23] Y. Yang, E. Y. Estrada, J. F. Thompson, W. Liu, and G. A. Rosenberg, "Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat," *Journal of Cerebral Blood Flow and Metabolism*, vol. 27, no. 4, pp. 697–709, 2007.
 - [24] R. E. Galarzy, D. Grobelny, H. G. Foellmer, and L. A. Fernandez, "Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide," *Cancer Research*, vol. 54, no. 17, pp. 4715–4718, 1994.
 - [25] K. Mishiro, M. Ishiguro, Y. Suzuki, K. Tsuruma, M. Shimazawa, and H. Hara, "A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice," *Neuroscience*, vol. 205, pp. 39–48, 2012.
 - [26] J. Dzwonek, M. Rylski, and L. Kaczmarek, "Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain," *FEBS Letters*, vol. 567, no. 1, pp. 129–135, 2004.
 - [27] R. J. Turner and F. R. Sharp, "Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke," *Frontiers in Cellular Neuroscience*, vol. 10, p. 56, 2016.
 - [28] M. Asahi, K. Asahi, J. C. Jung, G. J. del Zoppo, M. E. Fini, and E. H. Lo, "Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94," *Journal of Cerebral Blood Flow and Metabolism*, vol. 20, no. 12, pp. 1681–1689, 2000.
 - [29] S. Sole, V. Petegnief, R. Gorina, A. Chamorro, and A. M. Planas, "Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion," *Journal of Neuropathology and Experimental Neurology*, vol. 63, no. 4, pp. 338–349, 2004.
 - [30] Y. Suzuki, N. Nagai, K. Umemura, D. Collen, and H. R. Lijnen, "Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice," *Journal of Thrombosis and Haemostasis*, vol. 5, no. 8, pp. 1732–1739, 2007.
 - [31] M. Grossetete and G. A. Rosenberg, "Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse," *Journal of Cerebral Blood Flow and Metabolism*, vol. 28, no. 4, pp. 752–763, 2008.